TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35078620

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating age, Charlson Comorbidity Index (CCI), serum albumin, sodium, and hemoglobin.
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Serum albumin
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Sodium
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Hemoglobin
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: One-year mortality rate
Number of subjects: 454
Study: 32796255

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 23
Study: 34872952

Group type: EXPERIMENTAL
Intervention: Mendelian randomization techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic variants influencing alcohol consumption or LDL levels
Number of subjects: 0
Study: 32327398

Group type: EXPERIMENTAL
Intervention: MEDIHEALTH
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 142
Study: 33176924

Group type: EXPERIMENTAL
Intervention: Cemented metal-ceramic crowns
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cemented veneered zirconia crowns
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cemented monolithic zirconia crowns
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Non-cemented metal-ceramic crowns
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Non-cemented veneered zirconia crowns
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Non-cemented monolithic zirconia crowns
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Veneered zirconia after 20 hours of aging
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Monolithic zirconia after 20 hours of aging
Number of subjects: 72
Study: 32306608

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 192

Group type: COMPARATOR
Intervention: Thoracoscopy-laparoscopy-assisted surgery
Number of subjects: 192
Study: 33284959

Group type: EXPERIMENTAL
Intervention: Webinar group (Online presentation) - 260 subjects
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Face to Face lecture using PowerPoint presentation (F2F PP group) - 261 subjects
Number of subjects: 791

Group type: COMPARATOR
Intervention: Control group (Only lecture) - 270 subjects
Number of subjects: 791
Study: 35671231

Group type: EXPERIMENTAL
Intervention: BaSICS intervention (32-hour group-based intervention)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 113
Study: 33095935

Group type: EXPERIMENTAL
Intervention: Resting heart rate 70–74 beats/min
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Resting heart rate 75–80 beats/min
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Resting heart rate >80 beats/min
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Increment of 10 beats/min in resting heart rate among those with hypertension
Number of subjects: 788
Study: 32819962

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 0
Study: 33446078

Group type: EXPERIMENTAL
Intervention: Auditory-vocal task combined with a visual-manual task during seven practice sessions
Number of subjects: 0
Study: 35126620

Group type: EXPERIMENTAL
Intervention: Shuangshen Decoction combined with immunological preparations
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional treatment and immune agents (routine group)
Number of subjects: 90
Study: 33155422

Group type: EXPERIMENTAL
Intervention: Coronally Advanced Lingual Flap (CALF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Periosteal Releasing Incision (PRI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified Periosteal Releasing Incision (MPRI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Double Flap Incision (DF)
Number of subjects: 40
Study: 35900116

Group type: EXPERIMENTAL
Intervention: eHealth Mindful Movement and Breathing (eMMB)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Empathic attention control (AC)
Number of subjects: 31
Study: 33626166

Group type: EXPERIMENTAL
Intervention: Prompt treatment (≤ 6 days)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Delayed treatment (> 10 days)
Number of subjects: 625
Study: 32383449

Group type: EXPERIMENTAL
Intervention: Active mHealth follow-up (trimonthly phone calls to update vital status)
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Active mHealth follow-up
Number of subjects: 1490
Study: 34091120

Group type: EXPERIMENTAL
Intervention: Acquired antithrombin deficiency (AT<80%) at 72 hours post-admission
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Patients who developed VTE
Number of subjects: 579
Study: 33331917

Group type: EXPERIMENTAL
Intervention: Low plasma Aβ42/40 (≤0.107)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Plasma Aβ42/40 ratio > 0.107
Number of subjects: 483
Study: 35882054

Group type: EXPERIMENTAL
Intervention: Neutral trigger warning
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Positive trigger warning
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Negative trigger warning
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Higher PTSD scores
Number of subjects: 123
Study: 32947581

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based College (MB-College)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Enhanced usual care control
Number of subjects: 96
Study: 33017509

Group type: EXPERIMENTAL
Intervention: Vaginal Er:YAG LASER application
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oestrogen replacement
Number of subjects: 24
Study: 33646447

Group type: EXPERIMENTAL
Intervention: Autoimmune rheumatic diseases (ARD)
Number of subjects: 103117

Group type: EXPERIMENTAL
Intervention: Polymyositis and dermatomyositis (PM/DM)
Number of subjects: 103117

Group type: EXPERIMENTAL
Intervention: Systemic sclerosis (SSc)
Number of subjects: 103117

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus (SLE)
Number of subjects: 103117

Group type: EXPERIMENTAL
Intervention: Sjogren’s syndrome (SjS)
Number of subjects: 103117

Group type: EXPERIMENTAL
Intervention: Daily oral steroid dose of >10 mg
Number of subjects: 103117

Group type: EXPERIMENTAL
Intervention: Mycophenolate
Number of subjects: 103117

Group type: EXPERIMENTAL
Intervention: Other immunosuppressants (injected steroids, cyclophosphamide, biological agents, methotrexate, cyclosporine)
Number of subjects: 103117

Group type: EXPERIMENTAL
Intervention: Comorbidities (male sex, cancer, HIV, interstitial lung disease)
Number of subjects: 103117
Study: 32159882

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Gefitinib 250 mg once daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 81

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 81
Study: 34735310

Group type: EXPERIMENTAL
Intervention: Combined Training (CT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Multicomponent Training (MT)
Number of subjects: 2
Study: 33626088

Group type: EXPERIMENTAL
Intervention: Emotionally arousing segments identified based on HRV synchrony
Number of subjects: 21

Group type: COMPARATOR
Intervention: Randomly selected segments as control
Number of subjects: 21
Study: 32720384

Group type: EXPERIMENTAL
Intervention: High-dose omega-3 icosapent ethyl
Number of subjects: 3789

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3789
Study: 35443264

Group type: EXPERIMENTAL
Intervention: Open sky access osteotomy using a 2‐mm curved osteotome
Number of subjects: 40

Group type: COMPARATOR
Intervention: Percutaneous perforating method
Number of subjects: 40
Study: 32016876

Group type: EXPERIMENTAL
Intervention: Hybrid ANN-WOA model
Number of subjects: 217

Group type: COMPARATOR
Intervention: Core optimization models of ANN and MLR
Number of subjects: 217
Study: 98327681

Group type: EXPERIMENTAL
Intervention: 200 mg oral tolcapone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 mg intravenous tolcapone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Half of the recommended dosage of tolcapone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Moderate chronic hepatitis
Number of subjects: 24
Study: 33527488

Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 577

Group type: COMPARATOR
Intervention: Low-to-moderate intensity exercise
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: High intensity exercise with behavior change support (BCS)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Low-to-moderate intensity exercise with behavior change support (BCS)
Number of subjects: 577
Study: 36284318

Group type: EXPERIMENTAL
Intervention: Dabigatran (110 or 150 mg twice daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 200
Study: 33693475

Group type: EXPERIMENTAL
Intervention: Three-dimensional cell culture, spheroids, organoids, microfluidic devices, organ-on-a-chip systems, living animal and human cardiac tissues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive designs, master protocols, drug repurposing, in silico trials, N-of-1 trials
Number of subjects: 0
Study: 32860005

Group type: EXPERIMENTAL
Intervention: Forsythin (single oral administration)
Number of subjects: 0
Study: 32488889

Group type: EXPERIMENTAL
Intervention: Video-based dental health education (DHE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional dental health education (DHE)
Number of subjects: 60
Study: 34436562

Group type: EXPERIMENTAL
Intervention: Higher educational attainment (4.2 years of schooling)
Number of subjects: 14384

Group type: EXPERIMENTAL
Intervention: Higher educational attainment
Number of subjects: 14384

Group type: COMPARATOR
Intervention: Smoking exposure
Number of subjects: 14384

Group type: COMPARATOR
Intervention: BMI
Number of subjects: 14384

Group type: COMPARATOR
Intervention: Smoking and BMI combined
Number of subjects: 14384
Study: 33896622

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 60
Study: 34253047

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 7396

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 7396

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 7396

Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 7396
Study: 32612194

Group type: EXPERIMENTAL
Intervention: Sub-maximal running exercise (30 min at 80% heart rate reserve)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resting control
Number of subjects: 20
Study: 34936232

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hydrocodone/acetaminophen (APAP)
Number of subjects: 100
Study: 33342630

Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Polyvinylpyrrolidone Collagen (PVP)
Number of subjects: 26
Study: 34842189

Group type: EXPERIMENTAL
Intervention: Oral type 1 IFN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 0
Study: 32427014

Group type: EXPERIMENTAL
Intervention: Medication information (Med info)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Behavioral information (Beh info)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No change (control group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Reverse video (Rev Vid; also no change)
Number of subjects: 114
Study: 34851533

Group type: EXPERIMENTAL
Intervention: EM100 (eccentric phase velocity of 100%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EM150 (eccentric phase velocity of 150%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FW (conventional flywheel device)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 36256646

Group type: EXPERIMENTAL
Intervention: IB160 + 15μg H7N9
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: IB160 + 7.5μg H7N9
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: IB160 + 3.75μg H7N9
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: SE + 15μg H7N9
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: SE + 7.5μg H7N9
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: SE + 3.75μg H7N9
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: unadjuvanted vaccine 15μg H7N9
Number of subjects: 432

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 432
Study: 34609452

Group type: EXPERIMENTAL
Intervention: Subcutaneous scopolamine butylbromide, 20 mg four times a day (n=79)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo (n=78)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Subcutaneous scopolamine butylbromide
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 35852024

Group type: EXPERIMENTAL
Intervention: Smaller bottles (37.5-cl)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Smaller glasses (290 ml)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Larger bottles (75-cl)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Larger glasses (370 ml)
Number of subjects: 260
Study: 33346183

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saw techniques
Number of subjects: 100
Study: 34251396

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including seminars, online courses, management algorithms, communication tips, and feedback reports on antimicrobial prescribing.
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 426
Study: 32125875

Group type: EXPERIMENTAL
Intervention: Dynamic Intraligamentary Stabilization (DIS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Primary ACL Reconstruction (ACLR)
Number of subjects: 85
Study: 36302662

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study: 34391263

Group type: EXPERIMENTAL
Intervention: Finding-oriented manual therapy techniques (MTT), 9 treatments over a three-week period
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 9
Study: 32078510

Group type: EXPERIMENTAL
Intervention: Six Eye Exercises protocol (experimental group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-of-care protocol (control group)
Number of subjects: 20
Study: 35945582

Group type: EXPERIMENTAL
Intervention: Online self-help intervention based on Acceptance and Commitment Therapy (ACT) for 8 weeks with therapeutic email guidance
Number of subjects: 146

Group type: COMPARATOR
Intervention: Waiting list condition (WLC)
Number of subjects: 146
Study: 34698557

Group type: EXPERIMENTAL
Intervention: Theaflavins (TFs) for 6 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Theaflavins (TFs)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 32345348

Group type: EXPERIMENTAL
Intervention: Intense regimen of 12-h IO-therapy per day for 4 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard regimen of 4-h IO-therapy per day for 12 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intense regimen of IO-therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard regimen of IO-therapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: IO-therapy
Number of subjects: 56
Study: 35524938

Group type: EXPERIMENTAL
Intervention: Buprenorphine buccal film (BBF) 900 µg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oxycodone 60 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oxycodone 30 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 34587383

Group type: EXPERIMENTAL
Intervention: REGEN-COV 2400-mg
Number of subjects: 2696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2696

Group type: EXPERIMENTAL
Intervention: REGEN-COV 1200-mg
Number of subjects: 2696

Group type: EXPERIMENTAL
Intervention: REGEN-COV 2400-mg and 1200-mg
Number of subjects: 2696
Study: 34819266

Group type: EXPERIMENTAL
Intervention: Durvalumab + chemotherapy (platinum-based, ≤4 cycles) prior to surgery, followed by durvalumab monotherapy (q4w, for an additional 12 cycles post surgery)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo + chemotherapy (platinum-based, ≤4 cycles) prior to surgery, followed by placebo monotherapy (q4w, for an additional 12 cycles post surgery)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Durvalumab + chemotherapy
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo + chemotherapy
Number of subjects: 800
Study: 35757638

Group type: EXPERIMENTAL
Intervention: 3-week internet-based self-help intervention for COVID-19 related psychological distress
Number of subjects: 107
Study: 34703057

Group type: EXPERIMENTAL
Intervention: 0.1mg/kg dexamethasone (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1μg/kg dexmedetomidine (Group B)
Number of subjects: 100
Study: 33189633

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4796

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4796
Study: 32471469

Group type: EXPERIMENTAL
Intervention: myPlan Kenya app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 33278836

Group type: EXPERIMENTAL
Intervention: Orthodontic aligners (n 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fixed appliance (n 19)
Number of subjects: 38
Study: 32181747

Group type: EXPERIMENTAL
Intervention: Storytelling 4 Empowerment (S4E)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enhanced usual practice
Number of subjects: 50
Study: 36206385

Group type: EXPERIMENTAL
Intervention: 50 U aboBoNT‐A solution
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 33530511

Group type: EXPERIMENTAL
Intervention: Calcifediol weekly oral dose
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Weekly cholecalciferol
Number of subjects: 107

Group type: COMPARATOR
Intervention: Monthly cholecalciferol
Number of subjects: 107

Group type: COMPARATOR
Intervention: Single-dose cholecalciferol
Number of subjects: 107
Study: 32522090

Group type: EXPERIMENTAL
Intervention: Decision Regret Scale (DRS)
Number of subjects: 296
Study: 34715071

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 391
Study: 32301579

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification for interpretations (CBM-I)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Interpretation control condition (ICC)
Number of subjects: 24
Study: 35917774

Group type: EXPERIMENTAL
Intervention: Variable-rate infusion of norepinephrine
Number of subjects: 161

Group type: COMPARATOR
Intervention: Fixed-rate infusion of norepinephrine
Number of subjects: 161
Study: 32565595

Group type: EXPERIMENTAL
Intervention: 1 g hydroalcoholic extract of Fenugreek seeds daily for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 36334705

Group type: EXPERIMENTAL
Intervention: Enhanced intervention group (group-based DPP with weekly telephone support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study: 32043417

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) - dose-optimised (30–70 mg/day) or fixed-dose (70 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH) or atomoxetine (ATX)
Number of subjects: 0
Study: 33894078

Group type: EXPERIMENTAL
Intervention: Health activation measured using the Patient Activation Measure
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Challenges accessing care
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Health activation related to self-care
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Unique challenges in PSH
Number of subjects: 61
Study: 33630646

Group type: EXPERIMENTAL
Intervention: CDP-Choline 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDP-Choline 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDP-Choline 2000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDP-Choline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32000790

Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Arm-specific treatment delivered by a physiotherapist (Control Group)
Number of subjects: 40
Study: 34598780

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 312

Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 312
Study: 34145016

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine plus usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin plus usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxycycline plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33319846

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal direct current stimulation (tsDCS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study: 36244828

Group type: EXPERIMENTAL
Intervention: Normalization of CA-125 after 1 cycle of chemotherapy (defined as ≤35 U/mL)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Pattern of CA-125 change following chemotherapy cycle 1
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Percent decline of CA-125
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Absolute nadir normal value of CA-125 (0–10 vs. 11–35 U/mL)
Number of subjects: 350
Study: 33290346

Group type: EXPERIMENTAL
Intervention: Preoperative scalp block combined with incision line infiltration
Number of subjects: 56

Group type: COMPARATOR
Intervention: Postoperative scalp block combined with incision line infiltration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Preoperative scalp block
Number of subjects: 56

Group type: COMPARATOR
Intervention: Postoperative scalp block
Number of subjects: 56